Compare NOA & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NOA | VCRE |
|---|---|---|
| Founded | 1953 | N/A |
| Country | Canada | Sweden |
| Employees | N/A | N/A |
| Industry | Meat/Poultry/Fish | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 349.9M | 332.9M |
| IPO Year | 2006 | 2026 |
| Metric | NOA | VCRE |
|---|---|---|
| Price | $13.41 | $11.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 56.5K | 4.9K |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.77 | N/A |
| Revenue Next Year | $5.43 | N/A |
| P/E Ratio | $18.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.07 | $10.50 |
| 52 Week High | $17.26 | $13.00 |
| Indicator | NOA | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 41.46 |
| Support Level | $12.97 | $10.74 |
| Resistance Level | $14.51 | $11.59 |
| Average True Range (ATR) | 0.61 | 0.64 |
| MACD | -0.11 | 0.04 |
| Stochastic Oscillator | 2.52 | 38.80 |
North American Construction Group Ltd is Canada's heavy civil construction and mining contractor provider. The company has provided services to oil, natural gas, and resource companies. The Company provides a wide range of mining and heavy civil construction services to customer in the resource development and industrial construction sectors within Canada, the United States, and Australia. The Company's reportable segments are Heavy Equipment Canada, Heavy Equipment Australia, and Other. Heavy Equipment Canada and Heavy Equipment Australia include all of aspects of the mining and heavy civil construction services provided within those geographic areas. Other includes mine management contract work in the United States, its external maintenance and rebuild programs.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.